Skip to main content
Premium Trial:

Request an Annual Quote

Scripps Florida to Use GenoLogics Platform for Proteomics, Systems Bio Research

NEW YORK, Feb. 8 (GenomeWeb News) - Scripps Florida will use GenoLogics' lab- and data-management system in its proteomics and systems biology research, GenoLogics said today.

 

According to GeneLogics, Scripps Florida, a 2-year-old extension of the La Jolla, Calif.-based Scripps Research Institute, is focused on biomedical research, technology development, and drug design.

 

Its proteomics program focuses on developing and applying advanced technologies in mass spectrometry-based proteomics to answer questions on how proteins are modified by cells in certain diseases, GenoLogics said.

 

Nick Tsinoremas, senior director and head of informatics at Scripps Florida, said the center decided to work with GeneLogics because it wanted "a system that can cross over with other discipline areas, such as genotyping, microarray and gene expression."

 

Financial details were not discussed.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.